CORDIS
EU research results

CORDIS

English EN

Collaboration for Prevention and Treatment of MDR Bacterial Infections

Project information

Grant agreement ID: 853967

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    31 October 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 25 460 100

  • EU contribution

    € 8 000 000

Coordinated by:

UPPSALA UNIVERSITET

Sweden

Objective

The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2 AMR Accelerator will develop new agents to treat and prevent infections caused by MDR and XDR bacteria, including Mycobacterium tuberculosis and non-tuberculous mycobacteria. The COMBINE proposal addresses Pillar A, the Capability Building Network (CBN) of the AMR Accelerator programme.

The COMBINE consortium will form a Coordination and Support Office (CSO) that will support the delivery of projects across the AMR Accelerator, as well as with efficient communication among projects of the Accelerator and within the AMR community. In addition, we will establish an IT infrastructure that will allow for the FAIRification, collection, aggregation, storage, sharing, and analysis of vaccine and antibacterial preclinical and clinical data sets. When setting up the CSO, we will build on learnings from the two IMI ND4BB projects: ENABLE (an antibacterial discovery and development engine) and TRANSLOCATION (which has built an information centre for data sharing).

COMBINE partners will work to accelerate scientific discoveries in the AMR field by optimisation and standardisation of animal infection models, and development of improved models for translation of preclinical animal efficacy data and statistical analysis of clinical data. This will set new standards for the translational and predictive relevance of preclinical data and facilitate optimized design for new clinical trials. Results will feed into study and trial design throughout the AMR Accelerator to achieve more stringent and reliable development programmes.

Coordinator

UPPSALA UNIVERSITET

Address

Von Kraemers Alle 4
751 05 Uppsala

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 063 260

Participants (10)

BIOCOM

Germany

EU Contribution

€ 618 750

BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL

Germany

EU Contribution

€ 1 466 860

GRITSYSTEMS AS

Denmark

EU Contribution

€ 800 625

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 800 000

ASCLEPIA OUTSOURCING SOLUTIONS BVBA

Belgium

EU Contribution

€ 461 250

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 685 000

BEAM ALLIANCE

France

EU Contribution

€ 104 255

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

EVOTEC INTERNATIONAL GMBH

Germany

JANSSEN PHARMACEUTICA NV

Belgium

Project information

Grant agreement ID: 853967

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    31 October 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 25 460 100

  • EU contribution

    € 8 000 000

Coordinated by:

UPPSALA UNIVERSITET

Sweden